Qiqi Zhang

Hangzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Dynamic changes in Lamin B1 and heterochromatin coincide with chromatin condensation during human erythropoiesis.

Dynamic changes in Lamin B1 and heterochromatin coincide with chromatin condensation during human erythropoiesis.

Journal: Genome biology
Published: August 29, 2025

Iron-mediated ferroptosis impairs CAR-T cell function and antitumor efficacy.

Iron-mediated ferroptosis impairs CAR-T cell function and antitumor efficacy.

Journal: Nature cancer
Published: July 12, 2025

Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial.

Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial.

Journal: Nature medicine
Published: April 18, 2025

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies.

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies.

Journal: Experimental hematology & oncology
Published: August 29, 2024

Clinical characteristics and outcomes of BCMA-targeted CAR-T cell recipients with COVID-19 during the Omicron wave: a retrospective study.

Clinical characteristics and outcomes of BCMA-targeted CAR-T cell recipients with COVID-19 during the Omicron wave: a retrospective study.

Journal: Bone marrow transplantation
Published: August 28, 2024

Correction: CRISPR/Cas-based CAR-T cells: production and application.

Correction: CRISPR/Cas-based CAR-T cells: production and application.

Journal: Biomarker research
Published: July 22, 2024

CRISPR/Cas-based CAR-T cells: production and application.

CRISPR/Cas-based CAR-T cells: production and application.

Journal: Biomarker research
Published: December 25, 2023

HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy.

HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy.

Journal: Bone marrow transplantation
Published: December 30, 2022

Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.

Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.

Journal: Frontiers in immunology
Published: December 16, 2022

Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy.

Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy.

Journal: Journal of Zhejiang University. Science. B
Published: October 13, 2022

Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.

Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.

Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
Published: September 26, 2022

Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.

Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.

Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
Published: September 26, 2022
Showing 1-12 of 14

Last Updated: 09/26/2026